The Stanford Cancer Institute Office of Cancer Health Equity is dedicated to fostering and strengthening partnerships that improve research, education, and community outreach and engagement to reduce the cancer burden and cancer disparities.
Reena Thomas, MD, PhD, explains why glioblastoma, and brain cancer, can be challenging to treat and what innovations may help improve patients’ quality of life.
Stanford’s Department of Epidemiology & Population Health and the Stanford Cancer Institute launched an innovative new National Cancer Institute (NCI)-funded predoctoral T32 training program in cancer genetic epidemiology.
Christina Curtis, PhD, MSc, is the recipient of the 2024 American Association of Cancer Research Outstanding Investigator Award for Breast Cancer Research and the Susan G. Komen Brinker Award for Scientific Distinction in Basic Science. She is the...
Stanford is proud to have 32 scientists presenting oral abstracts, educational sessions, and workshops at the 2024 American Society of Hematology Annual Meeting, along with many poster presentations.
A promising Stanford Medicine treatment for deadly pediatric brain and spinal cord cancers received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration to expedite the approval process. By expediting...
A clinical trial investigating a promising blood cancer therapy treated its first patient in August 2024 after receiving fast-track activation from the Stanford Cancer Institute in March 2024.
Advancements in lung cancer care are improving individual patient outcomes and addressing the broader challenges of genetic risk factors and health disparities.
The Junior Faculty Forum fosters a culture of collaboration and support for early-career cancer researchers in basic, translational, clinical, and population sciences.
Stanford Cancer Institute members Allison Kurian, MD, MSc and Jennifer Caswell-Jin, MD, received a $3.5 million legacy gift to launch the Bright Pink Preventive Risk Outreach And Cascade Testing Program.
Stanford Cancer Institute member Frederick Dirbas, MD, speaks about the intersection of surgery and current radiation therapy treatment for breast cancer and the promise of more efficient radiation therapy with fewer side effects.
While some people with cancer have pre-existing disabilities, most patients are newly disabled as a result of their cancer diagnosis and encounter unique challenges related to their treatments.
Ten percent of childhood cancers are associated with a cancer predisposition syndrome caused by mutations to genes that prevent tumor growth or that drive cell growth and division.
One of the Stanford Cancer Institute’s core values is empowering the next generation of cancer scientists to find innovative solutions that improve patient outcomes. To uphold this value, we offer robust support to students, residents, fellows, and...
An increased understanding of the underlying mechanisms of cancer, cutting-edge technologies, and a seismic cultural shift toward a collaborative team science approach are helping researchers develop novel cancer drugs.
The emerging field of spatial biology holds promise in helping scientists gain an in-depth understanding of the tumor microenvironment and better predict patient outcomes.
Developing safe and effective allogeneic CAR-T cell therapies has been a long-standing focus for Stanford Cancer Institute member, Melody Smith, MD, MS
A lack of disclosure compounded by insufficient sexual orientation and gender identity data collection by providers can lead to a myriad of challenges in prostate cancer treatment.
Pamela Herena, director of clinical operations at the SCI Clinical Trials Office, shares her insight into the challenges and rewards of being an oncology nurse.
Stanford scientists illuminate the relationship between adoptively transferred T cells and macrophages and how two immunotherapies may work together to increase their tumor-fighting capabilities.
Thanks to the partnership with Stanford’s Advanced Melanoma Program and Blood and Marrow Transplantation (BMT) & Cellular Therapy Program, Stanford treated the first patient in the world with the newly approved TIL therapy.
Within the past couple of decades, the field of oncology has witnessed a shift to more curative treatments for patients with lung cancer, with radiation being a key factor in this new trajectory.
Cancer scientists at Stanford and the Children’s Hospital of Philadelphia (CHOP) identified a protein, FOXO1, that improves the survival and function of CAR-T cells, which may lead to more effective CAR-T cell therapies and could potentially expand...
In honor of the 2024 World Cancer Day theme, “Close the Care Gap,” we highlight a few Stanford cancer researchers working to close the care gap in diverse populations through screening, clinical trials, prevention, and community engagement.
The Stanford Cancer Institute Early Drug Development (EDD) program brings in early-phase clinical trials so cancer patients can have access to innovative treatments that could provide a therapeutic benefit.
Meryl Selig has had a unique experience at the Stanford Cancer Institute (SCI). She began as a patient volunteer in 2009 before being diagnosed with cancer and becoming a patient. She became one of the first patients to receive a novel chimeric...
CAR-T therapy has shown a great benefit in patients with hematologic and lymphatic cancers. However, applying the therapy to solid tumors has proven to be challenging. One of the barriers is T cell exhaustion, where the CAR-T cell becomes...
Stanford Cancer Institute member Elizabeth Kidd, MD, is developing new tools to facilitate the broader adoption of brachytherapy and ultimately improve outcomes for women facing cervical cancer.
On August 30, 2021, California adopted the Cancer Patients’ Bill of Rights, the first legislation of its kind in the United States. This legislation gives cancer patients inalienable rights to help them achieve access and equity in their care.
A study led by SCI members Summer Han, PhD, and Eunji Choi, PhD, and graduate student Chloe Su found that lung cancer survivors who have never smoked have the same risk as survivors who have smoked of developing secondary primary lung cancer (SPLC),...
Stanford is excited to have 26 presenters at this year's ASH Annual Meeting & Exposition. The Stanford Cancer Institute will also be hosting a booth at this year's conference.
During Gastric and Pancreatic Cancer Awareness Month, SCI member George Poultsides discusses his efforts to advance early detection of pancreatic cancer, improve personalized oncology, and direct Stanford's Surgical Oncology Fellowship program while...
Stanford Cancer Institute members Ash Alizadeh, MD, PhD, and Max Diehn, MD, PhD, have developed several novel techniques for early detection of cancer that rely on blood-based liquid biopsies.
We spoke with Stanford Cancer Institute (SCI) leaders to learn about advances in breast cancer treatment, issues affecting survivors, and bridging the racial inequities gap.
The overarching goal of the Cancer Therapeutics Program is to foster collaboration across scientific and clinical disciplines in order to gain deeper insights into cancer’s underlying causes and develop more effective diagnostic, prognostic, and...
SCI member Marvin Langston, PhD, was recently named a member of the inaugural cohort of Cancer Moonshot Scholars, which is part of the Biden Cancer Moonshot initiative. We spoke with him to learn more about his project that will be funded by the...
Recognizing the urgent unmet need for treating patients battling advanced melanoma, the Stanford Cancer Institute (SCI) is establishing the Stanford Advanced Melanoma Program—a world-class advanced melanoma center of excellence on the West Coast.
Stanford is excited to have 26 presenters at this year's ASH Annual Meeting & Exposition. The Stanford Cancer Institute will also be hosting a booth at this year's conference.
An article published recently in the Journal of Clinical Oncology presented a case study to highlight the value of using risk-prediction models as tools for patient-clinician communication on lung cancer screening.
The Asian Liver Center continues to uphold its pledge to address the disproportionately high rates of chronic hepatitis B infection and liver cancer in Asians and Asian Americans through community outreach, academic studies, and clinical expansion.
The Stanford Cancer Institute hosted five scholars from Howard University and Morehouse College in a summer research program for medical students from Historically Black Medical Colleges.
The program provides mentorship from SCI faculty members and hands-on lab experience for Stanford undergraduates interested in exploring cancer-related career tracks.
Since its establishment in 1978, the Stanford Cancer Biology PhD Program has been dedicated to training the next generation of exceptional scientists who will significantly contribute to cancer research.
SCI member Ruijiang Li, PhD, and colleagues have been developing a powerful approach to medical image analysis, utilizing a deep-learning program to predict treatment response and patient outcomes based on their routine CT and MRI scans, as well as...
Stanford Cancer Institute member Nam Bui, MD, sheds light on the crucial role of sarcoma centers during Sarcoma Awareness Month, offering insights into the future of sarcoma research.
The new 2023 FIGO endometrial cancer staging system has four stages, each of which contains substages that are determined by the cancer’s histological and molecular characteristics.
Immunotherapy has emerged as an important cancer therapeutics modality and is a significant cancer care advancement. CAR-T cell therapy has shown immense promise in paving the way for more effective cancer treatments.
The Stanford Cancer Institute Community Advisory Board plays a critical role in ensuring that the SCI meets the needs of our communities by threading our community's diverse perspectives and experiences into the fabric of the SCI's initiatives.
Stanford Cancer Institute member Quynh-Thu Le, MD, is the chair of the Stanford Department of Radiation Oncology and is recognized as a national leader in clinical trial research. We spoke with her about the research she’s most excited about and the...
Navigating cancer care can be overwhelming, but when combined with a disability, it becomes even more complex. Concerns about accommodations, potential dismissals, or changes to treatment options may arise.
To learn more about current melanoma treatment and advances in treatment, we talked with SCI member Allison Betof Warner, MD, PhD, leader of Stanford’s Melanoma & Cutaneous Oncology Clinical Research Group.
Wipe Out Melanoma’s main objective is to provide susceptible communities with the proper melanoma resources and education to catch the disease in its early stages when it is much more treatable.
With a menu of telehealth treatment options, including counseling, cessation medications, and digital health programs, patients and their family members have access to resources to aid them in their journey to get free from tobacco.
The Stanford Cancer Institute (SCI) Scientific Review Committee (SRC) is responsible for evaluating the scientific merit and progress of all human subject research trials involving cancer patients.
In observance of Colorectal Cancer Awareness Month and to learn more about recent advancements in the treatment and knowledge of CRC, we talked to SCI members George A. Fisher Jr., MD, and Steven M. Corsello, MD.
More than 200 Stanford Cancer Institute members, staff, and trainees gathered to share novel breakthroughs in cancer research, foster collaboration, and build community during this year’s retreat.
List of upcoming Stanford speakers at the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR)
SCI member Michael Binkley, MD, MS, has dedicated a significant amount of time to researching lymphoma, specifically focusing on an rare subtype of Hodgkin’s Lymphoma called nodular lymphocyte predominant Hodgkin’s lymphoma.
The American Cancer Society (ACS) has honored Dr. Lipika Goyal as Researcher of the Year. This award recognizes investigators who have benefitted from an American Cancer Society extramural grant and made remarkable advances in cancer research.
The Stanford Cancer Survivorship Program’s mission is to improve the experience and health outcomes of people living with and beyond cancer by advancing survivorship research and access to clinical services and educating healthcare professionals in...
We are delighted to announce that Rondeep (Roni) Brar, MD, clinical associate professor of Medicine, has been appointed Stanford Health Care’s Medical Director for the Cancer Destination Service Line (DSL) and Stanford Cancer Institute’s Associate...
On January 25, 2023, the National Institutes of Health (NIH) will require the submission of a Data Management and Sharing Plan (DMSP or DMP) with new proposals for projects generating scientific data.
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. While it is known how this disease takes root, Dr. Ravi Majeti and the team in the Majeti Lab are looking to tackle it at its source: stem cells.
Stanford Cancer Institute members Matthew Frank, MD, PhD, and David Miklos, MD, PhD, have received FDA breakthrough therapy designation for a large B-cell lymphoma trial.
Stanford Health Care’s Blood and Marrow Transplantation (BMT) and Cellular Therapy program recently hosted its 35th annual patient reunion. The celebration of life brought together over 400 patients, along with their loved ones, providers,...
Stanford Health Care’s (SHC) Blood and Marrow Transplantation & Cellular Therapy program performed its 500th Chimeric Antigen Receptor T-Cell Therapy (CAR T-cell) infusion.
We are thrilled to announce that Dinah Trevil, MPA, has joined the Stanford Cancer Institute (SCI) as the inaugural SCI Office of Cancer Health Equity Senior Program Director following a national search.
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
As an NCI Designated Comprehensive Cancer Center, the Stanford Cancer Institute (SCI)’s mission is to translate Stanford discoveries into individualized cancer care and prevention. In keeping with its important goal of educating and empowering the...
Kakada Ou, MD, is a physician from Cambodia who wants to establish the first Blood and Marrow Transplantation (BMT) Program in his country. He has spent several months working with Robert Negrin, MD, Division Chief of BMT at Stanford Medicine, to...
Research in pancreas cancer is essential to improving outcomes. In spring 2018, a group of Stanford Cancer Institute researchers and clinicians established the Pancreas Cancer Research Group (PCRG), a network of scientists interested in advancing...
Inside a tumor, molecules zip from place to place, and cluster in unusual areas, helping cancer cells multiply at a speedy pace. To stop tumors from growing, scientists often must aim to put the brakes on these molecules.
Tumor progression is assumed to be driven by ongoing mutation accumulation and selection, but researchers at the Stanford Cancer Institute have found that some tumors may be destined to invade or metastasize from the outset — they are “born to be...
Steven Artandi, MD, PhD, professor of medicine and of biochemistry at the School of Medicine, has been named the new Laurie Kraus Lacob Director of the Stanford Cancer Institute, effective October 1, 2018.
We are delighted to announce that Alyce Adams, PhD has been appointed Professor of Epidemiology and Population Health, inaugural Director of Stanford Cancer Institute’s (SCI) Office of Cancer Health Equity and SCI Associate Director for Community...
Stanford researchers show Mediator kinase module is a target for enhancing the potency of anti-tumor T cell responses and highlight the potential for gene editing technologies in cancer immunotherapy.
Letius sagittis at netus dictumst tristique ac suscipit augue sodales rutrum ex ridiculus fames venenatis molestie dapibus felis morbi volutpat maecenas aptent lacus ornare conubia bibendum tempor class quis tortor ad cras interdum litora accumsan...
We are proud to feature the voices of cancer research at Stanford, from the bench to the clinic. The SCI Spotlight connects with Stanford cancer researchers and trainees to provide insight into the work we are doing to diagnose, treat, and prevent...
Tumor progression is assumed to be driven by ongoing mutation accumulation and selection, but researchers at the Stanford Cancer Institute have found that some tumors may be destined to invade or metastasize from the outset — they are “born to be...
A Stanford study published July 26 in Nature demonstrates that cancer cells can be prompted to activate cellular death, a finding that has therapeutic applications in cancer treatment, regenerative medicine, and developmental disorders. The study...
